Pulmonary hypertension is defined as an increase of the mean pulmonary arterial pressure above 25 mm Hg and, as such, the diagnosis requires invasive haemo dynamic measurement by right heart catheterisation. More than just a single disease, pulmonary hyperten sion is an umbrella term that includes many different disorders and pathophysiological entities. However, most forms of pulmonary hypertension share a final common pathway, in particular the trias of vasocon striction, microthrombosis and vascular remodelling. The classification of pulmonary hypertension has been subjected to many changes within the last decade. At the same time, major achievements in our understand ing of the complex pathobiology have been made. Here, these developments are discussed in the light of the re cently published report from the fifth World Sympo sium on pulmonary hypertension.
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Definition and haemodynamics
Pulmonary arterial pressure (PAP) is a function of car diac output, left atrial pressure and pulmonary vascu lar resistance. The pulmonary circulation is a lowpres sure system and the mean pulmonary arterial pressure (mPAP) does not exceed 20 mm Hg in healthy individ uals [1] . Pulmonary hypertension is defined as an in crease of the mPAP above 25 mm Hg. Pressure values ranging from 21 to 24 mm Hg have been associated with a high risk to develop overt pulmonary hyperten sion in a subgroup of patients, for example those with connective tissue disease [2] , but otherwise these pa tients are not well defined and not much data exist on the prognostic and therapeutic consequences. Use of the term "borderline pulmonary hypertension" is thus not recom mended [3] . Increasing age [4] and body weight [5] have been associ ated with a rise of systolic pulmo nary arterial pressure (sPAP) and might explain the gap between nor mal mPAP and pulmonary hyper tension.
The presence of pulmonary hypertension might be determined by echocardiography, which, depending on the underlying cause of elevated pulmonary pressure, provides an excellent screening tool. However, sensitiv ity and specificity of this method is limited [6] . Diagno sis is thus confirmed by invasive haemodynamic as sessment with right heart catheterisation at rest. An inadequate elevation of pulmonary pressure upon ex ercise has been part of former definitions of pulmonary hypertension but, due to lack of standardisation, is no longer a criterion.
The differentiation of pulmonary hypertension due to left heart disease from the other forms is crucial. As suggested by guidelines, the pulmonary arterial wedge pressure (PAWP, also known as "wedge pressure") is used to estimate left atrial pressure in clinical practice. In healthy subjects, PAWP reflects left atrial pressure, which is extensively determined by left ventricular enddiastolic pressure (LVEDP). Several conditions in terfere with this assumption and may lead to misclas sification of pulmonary hypertension. Since pulmonary vessels are not stiff pipes but rather compressible tubes, an increase of the alveolar pressure (e.g., by pul monary disease, mechanical ventilation with positive endexpiratory pressure) may compress the pulmonary capillary bed. This phenomenon, known as the Starling resistor model [7] , explains the observation of elevated PAWP without underlying leftheart disease (leftatrial pressure and LVEDP are normal) in the context of pul monary diseases. Conversely, PAWP was found to be only a moderate discriminator in patients with normal or high LVEDP in one recent study [8] . When left heart REVIEW ARTICLE disease is strongly suspected in the evaluation of pul monary hypertension, concomitant measurement of LVEPD might be indicated. However, routine assess ment of pulmonary hypertension relies on measure ment of PAWP.
PAWP values ≤15 mm Hg define precapillary pul monary hypertension. PAWP values >15 mm Hg sug gest elevations of the pulmonary pressure by hydro static back pressure due to leftsided cardiac disorders, a condition which is coined postcapillary pulmonary hypertension. When the PAWP exceeds 15 mm Hg, the difference between diastolic pulmonary arterial pres sure (dPAP) and the PAWP further defines the pres ence of isolated postcapillary (dPAPPAWP <7 mm Hg) or combined pre and postcapillary pulmonary hyper tension (dPAPPAWP ≥7 mm Hg). The use of passive, reactive and "outofproportion" pulmonary hyperten sion has been abandoned in the context of left heart disease [9] .
Other haemodynamic parameters (table 1) such as cardiac output, pulmonary vascular resistance and transpulmonary pressure gradient are not required for diagnosis but help to identify the pathophysiological entities that result in elevated pulmonary pressure. Cardiac output is the mathematical product of heart rate and stroke volume (and, when further divided by body surface area, is referred to as cardiac index).
Pulmonary vascular resistance is calculated by in put pressure (i.e., mPAP) minus output pressure (i.e., PAWP,) divided by cardiac output (l/min) and is quanti fied by Wood units (mm Hg × min/l). Pulmonary vascu lar resistance is about 1 /10 of the systemic vascular re sistance. Wood units >3 indicate pulmonary hyperten sion, and, conversely, patients with values <3 are unlikely to have pulmonary hypertension. Pulmonary vascular resistance is not a part of the general definition of pulmonary hypertension and is not needed for the workup of all patients with pulmonary hypertension.
Vasoreactivity testing is mandatory only in the di agnostic workup of patients with idiopathic pulmonary arterial hypertension but is not recommended in all other forms of the disease [3] . Responders to vasoreagi bility testing (e.g. NO inhalation) are defined by a de crease of the mPAP of more than 10 mm Hg to an abso lute value <40 mm Hg without concomitant reduction of the cardiac output. Vasoresponders probably reflect an early state of the disease in which vasoconstriction predominantes. These patients are treated with cal cium channel blockers as first line treatment but re quire close followup since only half of them show long term responses [10] .
Recent studies suggest that occult left heart failure is common in patient with pulmonary hypertension [11] and misclassification of these patients might result in use of "PHtarget"therapies without evidence of benefit. The application of a fluid bolus (e.g., 250 or 500 ml sa line) during right heart catheterisation to identify these patients is not defined and routine application of this test cannot be recommended at the moment. Figure 1 shows the different pressure levels as sessed by right heart catheterisation. A modified "diag nostic algorithm" is provided in figure 2 [3, 12] . For clin 
Figure 1
Haemodynamic assessment. Swan-Ganz catheter [63] in situ.
For details see text. mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; LVEDP = left ventricular enddiastolic pressure.
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ical practice in cardiology, it is important to distinguish pulmonary hypertension due to left heart disease, the most common form that causes elevated pulmonary pressure, from other forms of pulmonary hypertension.
Classification and epidemiology
Pulmonary hypertension is a big umbrella term that summarises several diseases and entities that all re sult in elevation of the pulmonary pressure. According to a classification system used since 1998, pulmonary hypertension can be classified into five entirely differ ent clinical and pathophysiological groups (table 2) . Group 1, which is the main focus of this article, in cludes idiopathic and hereditary pulmonary arterial hypertension, pulmonary hypertension associated with different risk factors and predisposing conditions, pul monary venoocclusive disease, pulmonary capillary haemangiomatosis, persistent pulmonary hyperten sion of the newborn and congenital heart disease. Only group 1 is termed pulmonary arterial hypertension, while all the other groups are named pulmonary hyper tension. Much confusion is encountered in clinical practice with this nomenclature. Group 2 summarises pulmonary hypertension due to pathologies of the left heart [13, 14] , while the pressure elevation in group 3 is caused by diseases of the lung. These two groups in clude the most prevalent aetiologies for pulmonary hy pertension, although exact epidemiological data do not exist. Group 4 represents pressure elevation due to chronic thromboembolic events. Other miscellaneous conditions resulting in pulmonary hypertension, such as metabolic, haematologic and systemic disorders, are subsumed in group 5. The definitions of primary and secondary pulmonary hypertension are no longer used. With a prevalence of 5-15 cases per million [15] , pul monary arterial hypertension is considered to be an or phan disease. Pulmonary hypertension, however, is a very common condition. The most common causes for group 1 pulmonary hypertension include idiopathic and hereditary pulmo nary arterial hypertension, pulmonary arterial hyper tension in the context of connective tissue disease, con genital heart disease, portopulmonary hypertension in liver disease, druginduced pulmonary hypertension, and HIV infection ( fig. 3) [16] . Exact epidemiological data on the incidence of these forms is lacking and vary between different registries. The most common forms are shortly discussed here, for more details please refer to [17] .
Figure 2
Diagnostic approach to pulmonary hypertension. History and clinical signs might suggest the presence of pulmonary hypertension.
Step 1: Normal levels of NT-proBNP and absence of right heart hypertrophy in ECG have been described to have a high sensitivity to exclude pulmonary hypertension [64] . Echocardiography (TTE) is used as screening tool. mPAP might be estimated by adding the right ventricular to right atrial mean systolic gradient to right atrial pressure [65] or from the estimated systolic pulmonary pressure (right ventricular to right atrial maximal systolic gradient + right atrial pressure): mPAP = sPAP × 0.61 + 2 mm Hg [66] . When pulmonary hypertension is suggested by these screening tools, underlying heart disease (step 2) and chronic lung disorders (step 3) have to be excluded (RX = chest radiography; PFT = pulmonary function testing incl. diffusion capacity for carbon monoxide); BGA = blood gas analysis; HRCT = high-resolution computed tomography). In the absence of such conditions, chronic thromboembolic pulmonary hypertension is investigated by ventilation/perfusion scintigraphic or MR angiography [67] (step 4). Diagnosis of pulmonary hypertension is confirmed by right heart catheterisation and can further be classified in pre-and postcapillary elevation of pulmonary pressure. According to the levels of the diastolic pressure difference (DPD), postcapillary pulmonary hypertension is isolated or combined with precapillary pressure elevation (step 5). 
Hereditary pulmonary arterial hypertension
The most common mutations in pulmonary arterial hy pertension are lossoffunction mutations in the gene encoding for the bone morphogenetic protein receptor type II (BMPR2, see below), which is located on the long arm of chromosome 2 (2q33). Since the initial re port on BMPR2 mutation [18] more than 300 other ge netic variants have been identified in the context of pulmonary hypertension. These mutations can be found in about 70% of familial and in up to 30% of idio pathic forms of pulmonary arterial hypertension. These forms are thus summarised as hereditary pulmonary arterial hypertension. While several other mutations of downstream factors of BMPR2, coreceptors and other mediators have been described, changes in the expres sion of BMPR2 remain the ones with the most impor tance for prevalence and pathogenesis. Screening for such mutations is not recommended routinely and, in our centre, is rarely performed.
Connective tissue disease
Pulmonary hypertension is a comorbidity that can be found in all connective tissue diseases, including sys temic sclerosis, systemic lupus erythematosus, poly myo sitis/dermatomyositis (antisynthetase syndrome) [19] and rheumatoid arthritis. Epidemiological studies suggest that pulmonary hypertension is a common finding in patients with systemic sclerosis (more than 10% of patients [20] ). However, pulmonary hyperten sion in systemic sclerosis is complicated by the fact that elevation of pulmonary pressure can also be caused -or at least be aggravated -by parenchymal lung disease and left heart failure making it very diffi cult to identify the causative factor that results in ele vated pulmonary pressure [21] . Additional vasodilata tion of the pulmonary circulation may aggravate left heart failure and explain why patients with pulmonary hypertension associated with systemic sclerosis have a worse outcome when treated with PHtarget therapies compared to those with pulmonary arterial hyperten sion due to other aetiologies [22] . Patients with connec tive tissue disease should be screened with annual echocardiography or when developing symptoms.
Congenital heart disease / GUCH (grown-up congenital heart disease)
The prevalence of pulmonary arterial hypertension in adults with congenital heart defects (CHD) is not well defined. It is strongly influenced by the type of defect, and type and timing of surgical repair. Chronic expo sure of the pulmonary vascular bed to volume overload secondary to chronic high output and in particular to pressure overload (e.g. through ventricular or arterial shunts), may result in obstructive arteriopathy of pul monary vessels. The extreme form of pulmonary arte rial hypertension associated with CHD is Eisen menger's syndrome, where PVR equalises or exceeds systemic vascular resistance resulting in cyanosis and clubbing through bidirectional or reversal shunting [23] . In industrialised countries congenital heart de fects are usually diagnosed early in life and timely sur gical repair prevents development of pulmonary arte rial hypertension in most cases. As a result, the cohort of Eisenmenger patients is slowly decreasing in these countries. In developing countries Eisenmenger's syn drome is still prevalent. With modern heart surgery and cardiology care most patients with congenital heart disease now sur vive to adulthood, even those with complex lesions [24] . These adults are not cured. Some of these complex pa tients (i.e., Fontan circulation for singleventricle phys iology) may develop pulmonary vascular disease in longterm followup with adverse outcome [25] . Other types of pulmonary hypertension observed in the con text of CHD (e.g., congenital cardiomyopathies, inflow / outflow obstructions) belong to group 2.
Portopulmonary hypertension
Pulmonary arterial hypertension is present in 5-10% of patients with cirrhotic liver disease [26] . The exact pathogenetic mechanisms underlying elevation of pul monary pressure are not completely clear. Incomplete clearance of vasoconstrictive mediators by the diseased Figure 3 Epidemiology of pulmonary hypertension. Schematic representation of the 5 pulmonary hypertension groups (grey circles). The most prevalent aetiologies of pulmonary hypertension are group 2 (left heart diseases, PH-LHD) and group 3 (lung diseases, PH-LUNG). Group 1 (pulmonary arterial hypertension, PAH) is an orphan disease with different causes (prevalence according to [16] ). The prevalence of chronic thromboembolic pulmonary hypertension (CETPH) and of pulmonary hypertension due to miscellaneous aetiologies (PH-misc) is unknown. Portopulmonary hypertension is more common in fe male patients and in autoimmune hepatitis, whereas male gender and hepatitis C infection appear to be pro tective factors [28] . The therapy of coexisting liver and pulmonary hypertensive disease is a challenge particu larly because betablockers applied to reduce portal pressure and prevent variceal bleeding should not be used in pulmonary hypertension. In addition oral anti coagulation is contraindicated in liver disease because of the risk of coagulopathies. Finally, PH target thera pies might be hepatotoxic and orthotopic liver trans plantation is difficult to perform in the presence of pul monary hypertension.
PH-LHD

Drugs and toxins
Several drugs and toxins have been investigated for an association with the development of pulmonary arte rial hypertension. A causative role has been proposed for several anorexigens including a recent report on Benfluorex in France [29] , and selective serotonine re uptake inhibitors in pregnant women that result in pulmonary arterial hypertension of the newborns. Il licit drugs such as cocaine and amphethaminelike drugs show a possible association. The tyrosine kinase inhibitor dasatinib has recently been associated with pulmonary hypertension [30] and, following initial enthusiasm in case reports [31, 32] the use of tyrosine kinase inhibitors for pulmonary hypertension is now questioned [33] . An association is less likely for oral contraceptives and oestrogens. The role of smoking is controversial but prevalence of smoking appears to be higher in patients with pulmonary arterial hyperten sion [34] . In addition, smoking is associated with in creased vascular remodelling in pulmonary arteries [35] and significant reduction of diffusion capacity [36] .
Human immunodeficiency virus
HIV patients have an increased prevalence for pulmo nary arterial hypertension [37] . Current epidemiologi cal data suggest that about 0.5% of HIV patients de velop elevated pulmonary arterial pressure. The patho genesis of HIVassociated pulmonary hypertension is unclear, but chronic inflammation is thought to be of importance. The interesting data on the causative role of human herpesvirus8 [38] (which is responsible for the development of Kaposi Sarcoma and lymphoprolif erative Castleman's disease) have not been confirmed. Whether antiretroviral treatment might also reduce pulmonary arterial pressure remains controversial but it has been shown that prolonged treatment of subjects with HIVrelated pulmonary hypertension results in normalisation of elevated pulmonary pressure in about one third of patients and is associated with reduced mortality [39] .
Pathobiology
In the update from Nice 2013 on the clinical classifica tion of pulmonary hypertension almost 30 entities are listed as different aetiologies for pulmonary hyperten sion. Of interest, most of these forms result in the small pulmonary arteries (<300 μm) in a final common path way of vasoconstriction, microthrombosis and vascular remodelling ( fig. 4 ). This makes it impossible to distin guish different aetiologies in established disease by, for example, pathomorphology of pulmonary vessels.
Vasoconstriction
Vasoconstriction without microthrombosis and vascu lar remodelling possibly reflects an early and probably reversible stage of disease. Contraction of vascular smooth muscle cells, mainly mediated by excessive re lease of intracellular calcium [40] , is due to a dysbal ance of vasoactive factors. For example, elevated levels of endothelin1, one of the strongest vasoconstrictors, detected in the circulation of patients with pulmonary arterial hypertension, correlate positively with haemo dynamic parameters such as mPAP [41] . Conversely, the production of the vasorelaxative factor nitric oxide and its second messenger cyclic guanosine monophos phate (cGMP) are reduced in patients with pulmonary arterial hypertension [42] . Similarly, relaxative prosta cyclins and cyclic adenosine monophosphate are re duced in vessels of patients with pulmonary arterial hypertension [43] . Most currently used PHtarget ther apies are specific vasodilators that interact with one of these systems. In addition, cardiopulmonary reflexes might trigger or -by a vicious cycle of hypoxia and va soconstriction -aggravate the constriction of pulmo nary arteries. The most important reflex in this context REVIEW ARTICLE is the EulerLiljestrand reflex, which describes a para doxical response of pulmonary artery smooth muscle cells to hypoxia and which minimises ventilation / per fusion mismatch in the lung by directing blood flow to ventilated areas. The HermoWeiler (or Kitaev)reflex is important for the development of pulmonary hyper tension in left heart disease and describes vasocon striction of precapillary pulmonary arteries upon pres sure increase of the left atrium (reviewed in [44] ).
Microthrombosis
It is well known that in situ thrombotic events within small pulmonary arteries are common in patients with pulmonary arterial hypertension and occur more fre quently with longer duration of the disease and in creasing age of the patient. Several abnormalities in the coagulation system have been described including reduced anticoagulatory activity of protein C and S, in creased activity of von Willebrand factor and reduced fibrinolysis by increased expression of the plasminogen activator inhibitor [45] [46] [47] . The increased coagulability with thrombosis contributes to the pathobiologic evolu tion of the disease and justifies the use of oral antico agulation in patients with pulmonary arterial hyper tension [48] .
Vascular remodelling
Vascular remodelling is arguably the most important pathogenetic event in the development of pulmonary arterial hypertension. In contrast to vasoconstriction and microthrombosis which can be treated successfully, vascular remodelling of small pulmonary arteries is recognised as the main cause of the chronicity and pro gression of pulmonary hypertension and explains the refractoriness of the disease to current therapeutic reg imens. This remodelling is characterised by an exces sive proliferation of vascular smooth muscle cells and the formation of a neointimal layer, which result in in creased thickness of the pulmonary arterial vessel wall and occlusion of the vascular lumen [49, 50] . With the exception of plexiform lesions, which are focal prolifer ations of endothelial channels lined by myofibroblasts [51] and a characteristic feature of group 1 pulmonary arterial hypertension, the pattern of vascular remodel ling is indistinguishable between the different aetiolo gies of elevated pulmonary pressure [52] . A character istic example of vascular remodelling in pulmonary hypertension is provided in figure 5 . Despite many advances, the pathogenesis of the vascular remodelling is still a matter of debate. It has been demonstrated that a complex network of different factors, including growth factors, neurohumoral trans mitters, infections, inflammatory cells, cytokines, chemokines and voltagegated potassium channels, contribute to the remodelling process. A major role in triggering vascular remodelling has been attributed to the bone morphogenetic protein receptor type II (BMPR2). The BMPR2 is a member of a family of growth factor receptors (transforming growth factor beta receptors) and located at the surface of endothelial and vascular smooth muscle cells. Mutations in the BMPR2 result in increased cell survival and prolifera tion, and have been identified as causative factors in the development of hereditary pulmonary arterial hy pertension. The fact that BMPR2 mutations can be found in up to 70% of families with pulmonary hyper tension and in up to one third of patients with idio pathic pulmonary arterial hypertension indicate that additional factors are responsible for the development and progression of pulmonary hypertension. In recent years, it has become clear that in many nongenetic forms of pulmonary hypertension -such as congenital heart disease [53, 54] , HIVinfection [55] , left heart dis ease [54] and chronic hypoxia including the major ex perimental models of the disease [56, 57] -the BMPR2 is downregulated and its signalling pathways are dys functional. This downregulation might be due to the action of microRNAs (i.e., small noncoding RNA frag ments) that bind to the mRNA of the BMPR2 and in hibit its translation [58] . The use of BMPR2 transfection in case of genetic mutations or the application of antag omiRs that inhibit microRNAs specifically in nonge netic forms of the disease have been shown to prevent 
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or treat vascular remodelling and improve haemody namics in experimental models of the disease [59] [60] [61] [62] .
Whether such an approach for a "reverse remodelling" is feasible and successful in human disease remains to be elucidated.
